

A short, stereoselective, and common approach for the synthesis of 4,5-disubstituted δ -lactones simplactone B and its C-5 analogue[☆]

A. Ravi Kumar,^a N. Sudhakar,^a B. Venkateswara Rao,^{a,*} N. Raghunandan,^b
A. Venkatesh^b and M. Sarangapani^b

^aOrganic Chemistry Division III, Indian Institute of Chemical Technology, Hyderabad 500007, India

^bUniversity College of Pharmaceutical Sciences, Kakatiya University, Warangal 506009, India

Received 2 November 2004; accepted 15 February 2005

Available online 19 March 2005

Abstract—A short, stereoselective, and a common approach for the synthesis of 4,5-disubstituted δ -lactones simplactone B and its analogue using Evans protocol is described.

© 2005 Elsevier Ltd. All rights reserved.


1. Introduction

Many natural products, which contains γ - and δ -lactone moieties isolated from marine and terrestrial natural sources differing in chain length, branching and functionalization of alkyl chain, possesses interesting and peculiar biological activities.¹ Hitherto a number of γ - and δ -lactones are isolated, possessing activities like antifungal and antibiotic activities. Among these, recently simplactone A and B compounds were isolated from the Caribbean sponge,² *Plakortis simplex* and these compounds possesses in vitro cytotoxic activity against WEHI 164. Some other interesting δ -lactones are homomevanolactone,³ a structural isomer of simplactones, malyngolide,^{4a,b} etc.,^{4c} which possess long alkyl chains.


Some of the γ - and δ -lactones, which contain long alkyl chain unit mainly possess antibiotic and antifungal

activities. Cafieri et al.² expressed that incorporation of long alkyl chains may increase the activity of simplactones. Herein we report the novel and short strategy for the synthesis of simplactone B and its C-5 analogue using asymmetric aldol reaction. This strategy is also helpful to make analogues with various chain lengths. Sato et al.⁵ synthesized simplactones A and B and they proposed that these spectral values are identical with the proposed (isolated) simplactones B and A, respectively, rather A and B. Our synthesis gives strong evidence to the above statement because the spectral data of simplactone B which we synthesized is identical with the proposed (isolated) simplactone A (see Scheme 1).


Our synthetic route for simplactones involves Evans asymmetric aldol methodology to set up the stereochemistry of the two contiguous stereogenic centers. Compound **4** was coupled with corresponding different



Simplactone A 1
(Proposed)



simplactone B 2
(Proposed)




C-5 analogue of simplactone **3**

Keywords: Chiral auxiliary; Evans-asymmetric aldol methodology; Tempo oxidation; δ -Lactones; Cytotoxic activity.

[☆]IICT Communication number: 040707.

* Corresponding author. Tel.: +91 040 271 60123x2614; fax: +91 040 271 60512; e-mail: venky@iict.res.in



Scheme 1. Reagents and condition: (a) $\text{CH}_3\text{CH}_2\text{CH}_2\text{COOH}$ (for **5a**), $\text{C}_{15}\text{H}_{31}\text{COOH}$ (for **5b**), pivaloyl chloride, Et_3N , LiCl , THF, -20°C , 5 h, 95% for **5a**, 96% for **5b**; (b) Bu_2BOTf , Et_3N , -78°C , 1 h, then $\text{CHO}(\text{CH}_2)_2\text{OBn}$ (**6**), -78°C to -10°C , 2 h, 82%, for **7a**, 81% for **7b**; (c) aq NaBH_4 , THF, 0°C to rt, 2 h, 96% for **8a**, 95% for **8b**; (d) 2,2-DMP, CH_2Cl_2 , PTSA (Cat amount), rt, 8 h, 97% for **9a**, 95% for **9b**; (e) Li/liq NH_3 , -78°C , 0.5 h, 91%, for **10a**, 92% for **10b**; (f) NaOCl , TEMPO free radical, TBAI (cat. amount), NaBr , EtOAc , toluene, H_2O , NaHCO_3 , rt, then PTSA, CH_2Cl_2 , rt, 3 h, 72% for **2**, 73% for **3**.

acids in the presence of pivaloyl chloride and triethyl amine to get **5a,b**. Treatment of the boron enolate⁶ derived from compounds **5a,b** with the aldehyde **6** provided **7a** in 82% and **7b** in 81% yield, which were converted to diols **8a,b** after removing the oxazolidinone auxiliary with aq NaBH_4 . Then the diols underwent acetonide protection using 2,2-DMP to get compounds **9a,b**, which on treatment with Li/liq NH_3 conditions yielded **10a,b**. Under Tempco oxidation conditions **10a** and **b** were converted to acids, which were simultaneously treated with PTSA in DCM to afford lactones **2** and **3**, in one pot. The spectral data of **2** is well in agreement with the reported values, whose optical rotation value ($[\alpha]_{\text{D}}^{25} -23.1$ (c 1, CHCl_3)) is matching with the synthetic compound prepared by Sato et al. {lit.⁵ (synthetic) $[\alpha]_{\text{D}}^{25} -23.9$ (c 0.8, CHCl_3)}. Whereas optical rotation value of natural product is lower than the synthetic compounds. {lit.² (natural) $[\alpha]_{\text{D}}^{25} -3$ (c 0.002, CHCl_3)}.

We have evaluated both lactones **2** and **3** for cytotoxic activity against human breast cancer cell lines (HBL-100) by MTT method.⁷ Compound **3**⁸ (C-5 analogue) possesses moderate cytotoxic activity with IC_{50} of $0.176\ \mu\text{M}$, whereas on these cell lines lactone **2** has not shown any activity. This clearly shows that side chain length variation of these lactones will certainly influence the activity.

In summary we have developed a short and highly stereoselective synthesis of δ -lactones using the well-known diastereoselective Evans protocol which is useful to make analogues of different chain lengths for more therapeutic activity.

Acknowledgements

A.R.K. and N.S.R. thank CSIR and U.G.C. New Delhi, for their research fellowship. We also thank Dr. J. S.

Yadav and Late Dr. A. K. Singh for their support and encouragement and Dr. S. Chandrasekhar for his help.

References and notes

- Guzman, D.; Schmitz, F. J. *J. Nat. Prod.* **1990**, *53*, 926–931.
- Cafieri, F.; Fattorusso, E.; Tagliatela-Scafati, O.; Di Rosa, M.; Ianaro, I. *Tetrahedron* **1999**, *55*, 13831–13840.
- (a) Jennings, R. C.; Judy, K. J.; Schooley, D. A. *J. Chem. Soc., Chem. Commun.* **1975**, 21–22; (b) Lee, E.; Schooley, D. A.; Hall, M. S.; Judy, K. J. *J. Chem. Soc., Chem. Commun.* **1978**, 290–292.
- (a) Cardellina, J. H., II; Moore, R. E.; Arnold, E. V.; Clardy, J. *J. Org. Chem.* **1979**, *44*, 4039–4042; (b) Enders, D.; Knopp, M. *Tetrahedron* **1996**, *52*, 5805–5818; (c) Toshima, H.; Watanabe, A.; Sato, H.; Ichihara, A. *Tetrahedron Lett.* **1998**, *39*, 9223–9226.
- Sato, M.; Nakashima, H.; Hanada, K.; Hayashi, M.; Honzumi, M.; Taniguchi, T.; Ogasawara, K. *Tetrahedron Lett.* **2001**, *42*, 2833–2837.
- Evans, D. A.; Batroli, J.; Shih, T. L. *J. Am. Chem. Soc.* **1981**, *103*, 2127–2129.
- Feasibility of high flux anti-cancer drug screen using diverse panel of cultured human tumor cell lines. (a) Monks, A.; Scudiero, P.; Shoemaker, J. *Natl. Cancer Inst.* **1991**, *83*, 11; (b) Scudiero, D. A.; Shoemaker, R. H.; Paul, K. D. Evaluation of soluble tetrazolium/formazan assay for cell growth and drug sensitivity in cultures using human and other tumor cell lines. *Cancer Res.* **1988**, *48*, 4827–4833; (c) Alley, M. C.; Scudiero, D. A.; Monks, A. Feasibility of drug screening with panels of human tumor cell lines using microculture tetrazolium assay. *Cancer Res.* **1998**, *48*, 589–601.
- Spectral data for compound **3**: $[\alpha]_{\text{D}}^{25} -3.07$ (c 1.1, CHCl_3); Mp: 74°C ; (^1H NMR, 400 MHz, CDCl_3): δ 0.9 (t, 3H, $J = 6.2$), 1.2–1.45 (m, 24H), 1.51–1.62 (m, 1H), 1.77–1.95 (m, 2H), 2.5 (dd, 1H, $J = 6.1$, 17.7), 2.84 (dd, 1H, $J = 5.3$, 16.9), 3.92 (t, 2H, $J = 10.1$), 4.46 (dd, 1H, $J = 3.8$, 11.5); (^{13}C , 75 MHz, CDCl_3): 170.3, 69.3, 68.4, 41.1, 38.2, 31.9, 29.6, 29.4, 29.3, 28.8, 26.8, 22.6, 14.03. FABMS: ($\text{M}^+ + 1$) 313.